Bausch Health Companies (BHC) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Liquidia (LQDA) has outperformed Bausch Health Companies (BHC) over the past year, gaining 16.4% versus a loss of 4.7%. Over five years, LQDA leads with a +775.6% price change compared with -78.8% for BHC. Liquidia is the larger company by market cap ($2.51 billion vs $2.26 billion), about 1.1 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 11.7x for Liquidia).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | LQDA |
|---|---|---|
| Share price | $6.04 | $28.02 |
| Market cap | $2.26B | $2.51B |
| 1-day change | -1.79% | +5.02% |
| YTD return | -13.09% | -18.76% |
| 1-year return | -4.73% | +16.36% |
| 5-year return | -78.80% | +775.63% |
| P/E ratio (TTM) | — | 20.16 |
| Forward P/E | 1.44 | 11.66 |
| EPS (TTM) | $-2.95 | $1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $93.61 |
| 52-week low | $4.33 | $21.94 |
| Distance from 52-week high | -24.50% | -70.07% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +24.17% | +77.27% |
| Average volume | 3.24M | 2.40M |
| Shares outstanding | 373.99M | 89.51M |
| Employees | 20,300 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed BHC by 21.1 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
BHC vs LQDA FAQ
Which is bigger, Bausch Health Companies or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $2.51B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or LQDA?
LQDA returned +16.36% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.